Healthcare

EVE Health Group (ASX:EVE) has commenced its first clinical study for Libbo, an oral soluble film formulation of the erectile dysfunction medicine vardenafil.

Imricor Medical Systems (ASX:IMR) has submitted the final devices required for its U.S. regulatory pathway, bringing its interventional cardiac MRI (iCMR) platform closer to full product clearance in its largest target market.

Aroa Biosurgery (ASX:ARX) has secured further visibility around the U.S. reimbursement environment for its Symphony wound-care product, with the Centers forMedicare& Medicaid Services (CMS) proposing to maintain the existing outpatient skin substitute payment framework through Calendar Year 2027.

Amplia Therapeutics (ASX:ATX) has signed a Clinical Trial Collaboration andSupplyAgreement with Eli Lilly to evaluate its oral FAK inhibitor narmafotinib in combination with Lilly's KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer (NSCLC).

Avecho Biotechnology (ASX:AVE) has cleared a key milestone in its Phase III insomnia program after an independent Data Safety Monitoring Board (DSMB) recommended the study continue to its full planned enrolment of 519 participants without increasing patient numbers.

Chimeric Therapeutics (ASX:CHM) has reported early tumour-shrinkage data from the highest dose tested so far in its CHM CDH17 CAR-T cell therapy trial, with two of four patients showing individual lesion shrinkage between 17% and 40%.

CSL Limited (ASX:CSL) has confirmed it will progress its next-generation plasma processing technology, known as Horizon 2, into human clinical trials as the company seeks to improve immunoglobulin production efficiency from donated plasma.